Strand Bags Indian Patent for Blood-Based Cancer Test

Reliance-backed Strand Life Sciences recently secured an Indian patent for an innovative liquid biopsy platform. Consequently, this technology significantly improves early cancer detection by analyzing cell-free DNA from a simple blood sample. Such advancements are vital for professionals interested in the evolving field of precision oncology.

How the Patented Liquid Biopsy Technology Works

First, the platform analyzes fragments of cell-free DNA circulating in the bloodstream. Specifically, the technology combines high-quality genome sequencing with rigorous quality control. Therefore, it reliably extracts biologically informed methylation and fragmentomic features. Subsequently, advanced machine learning algorithms analyze these complex data points. Ultimately, this integration allows clinicians to detect cancer and accurately predict its tissue of origin.

Why Genome Methylation Patterns Matter

Methylation changes represent a classic hallmark of early-stage oncological development. However, traditional screening methods often fail to capture these subtle genomic variations. Fortunately, this newly patented system captures widespread methylation changes with minimal loss. Indeed, this capability remains critical for improving diagnostic sensitivity. As a result, healthcare providers can diagnose malignancies long before patients show advanced physical symptoms. Those looking to deepen their expertise in diagnosing such conditions may explore the Certification Course In Clinical Oncology.

The Future of Early Cancer Detection in India

Currently, India faces a rapidly growing public health crisis with over 1.5 million new cancer cases annually. Unfortunately, late-stage diagnoses severely limit treatment choices. To address this, the patented AI platform leverages decreasing sequencing costs to enable scalable screenings. Moreover, this approach works without expanding local hospital infrastructure. Ultimately, it makes oncology services highly accessible across diverse regions.

Frequently Asked Questions

Q1: What is cell-free DNA (cfDNA) and how does Strand Life Sciences use it?

Cell-free DNA consists of tiny DNA fragments that dying tumor cells release into the bloodstream. Strand Life Sciences analyzes these fragments using genome sequencing to detect cancer patterns without requiring invasive tissue biopsies.

Q2: Why is predicting the tissue of origin important?

Predicting the tissue of origin allows physicians to determine where the cancer first developed. Consequently, doctors can target their diagnostic scans and treatments much faster, saving critical time for patients.

References

1. Reliance’s Strand Life Sciences secures Indian patent for blood-based earlycancer detection technology – ETHealthworld
2. RIL’s Strand Life Sciences Wins Indian Patent for AI-powered Blood-based Early Cancer Detection – Moneylife
3. Strand Life Sciences Bags Patent for AI Cancer Detection Tech – Whalesbook

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.